查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1832132

解剖病理学检测市场（按检测类型、样本类型、应用和最终用户划分）—2025-2032 年全球预测

Anatomic Pathology Testing Market by Test Type, Sample Type, Application, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年解剖病理学测试市场将成长至 740.1 亿美元，复合年增长率为 6.40%。

主要市场统计数据
基准年2024年 450.3亿美元
预计2025年 479.2亿美元
预测年份：2032年 740.1亿美元
复合年增长率（%） 6.40%

整合技术创新、不断变化的临床需求、实验室工作流程和政策驱动因素的解剖病理学检测趋势概述

解剖病理学检测正处于临床需求与快速技术创新的交汇点，推动着人们对诊断准确性、週转时间以及与治疗决策整合的全新期望。如今，在实验室和诊断服务机构所处的环境中，分子表征、免疫分析和影像主导分析必须与传统的组织学工作流程共存，以支持精准医疗路径。因此，临床、研究和商业领域的相关人员正在重新调整投资、伙伴关係和营运流程，以应对日益复杂的临床需求，同时控製成本并确保合规性。

此外，医疗保健服务模式的转变（从门诊肿瘤项目到集中式参考实验室）正在改变检体流程、检测量和诊断决策场所。因此，实验室负责人不仅在评估数位和分子工具集的诊断价值，还在评估其与电子健康记录、实验室资讯系统和多学科护理团队的整合能力。鑑于这些动态，以下高阶主管综合报告确定了再形成实践的关键驱动因素、需要策略应对的结构性挑战，以及决策者在优先考虑人员、技术和伙伴关係关係投资时应权衡的实际因素。

深入检验正在重塑诊断途径、资料架构和实验室人员的变革性技术、临床和监管变化

解剖病理学领域正在经历数次变革，这些变革正在改变诊断方式、实验室运作方式以及数据在相关人员之间的流动方式。许多机构已将数位病理学从试点阶段推进到实际应用阶段，实现了全切片成像、远端审查和演算法影像分析的应用。同时，人工智慧和机器学习在日常工作流程中的普及，为诊断演算法检验、临床整合和监管审批带来了新的考量。

同时，次世代定序、萤光原位杂合反应和标靶 PCR 等分子病理学技术正在重新定义诊断类别和治疗分层。这种分子生物学扩展需要组织病理学和分子生物学实验室之间加强合作，对生物资讯学、资料储存和跨学科培训的需求也日益增加。监管关注和报销框架也在不断发展。因此，实验室必须应对不断变化的验证期望和价值证明要求。最后，实验室面临实验室紧张、供应链不稳定以及对更快週转时间日益增长的需求，这促使它们寻求自动化、简化的工作流程和策略供应商合作伙伴关係，以维持品质和产量。总之，这些转变正在重塑采购、劳动力发展和临床服务设计的优先事项。

重点分析2025年美国关税改革如何改变供应链、采购策略、试剂采购和跨境实验室运营

美国关税政策在2025年之前的演变，将对从事解剖病理学检测的实验室、製造商和经销商产生复杂的营运和策略影响。短期内，进口设备、试剂和耗材关税的提高，迫使采购团队重新评估筹资策略，增加关键试剂的库存缓衝，并加快供应商资格资格确认流程，以降低供应中断的风险。因此，采购週期通常包含紧急条款、替代供应商清单和加速检验途径，以确保临床服务的连续性。

从中期来看，这些贸易行动凸显了供应商多元化和区域采购的经济和物流价值。一些临床实验室和製造合作伙伴正在寻求更紧密的製造合作，扩大製造外包，并实现仓储本地化，以降低运费波动和关税风险。同时，製造商正在重新审视产品设计和零件采购，以减少受关税影响零件的风险，而服务机构也正在重新评估其维护和备件策略。当供应商更换来源时，也会产生监管和合约方面的影响。因此，机构必须确保替换零件符合原始性能和监管基准。

此外，关税主导的成本压力可能会加速围绕自动化和检测整合的讨论，这将减少对进口耗材的逐项检测依赖。为了因应这些压力，相关人员越来越重视情境规划、包含对冲条款的多年期供应商合约以及与供应伙伴的协作预测。总而言之，2025 年的关税趋势正在推动策略转变，转向供应弹性、采购敏捷性以及加强产业与实验室之间的协作，以保障诊断的连续性。

按测试类型、样本类型、应用程式和最终用户进行细分，以揭示采用动态、技术协作和优先级

按测试类型分析表明，实验室正在建立混合诊断工作流程，在传统组织学技术与新兴的数位和分子模式之间取得平衡。数位病理学正在吸引对影像分析软体和玻片扫描仪的投资，这些软体和扫描仪可以进行远端审查和高级形态学分析，而苏木精-伊红染色仍然是基本的组织评估方法。免疫组织化学继续扩大其在诊断和预测测试中的作用，实验室根据检测特异性和供应可靠性使用单株和多株抗体策略。分子病理学已成为组织学的核心补充。诊断组合结合了萤光原位杂合反应、次世代定序和聚合酵素链锁反应等方法，以捕捉基因组变异和可操作的生物标记。特殊染色技术，如过碘酸-希夫染色、银染色和三色染色，对于特殊诊断情况和区分疾病形式非常重要。

在考虑样本类型时，细胞学样本、冷冻切片和组织切片检查之间的差异决定了不同的分析前处理、预期週转时间和设备需求。这些针对检体的具体要求决定了实验室所采用的工作流程和验证策略。在应用方面，检测程序针对遗传疾病评估、感染疾病检测和肿瘤学诊断进行调整。遗传评估进一步分为染色体异常和单基因异常的工作流程，传染病检查区分细菌和病毒病原体的检测策略，肿瘤学通讯协定优先考虑肿瘤特异性检测组，例如用于乳癌、肺癌和前列腺癌的检测组。最后，最终用户（诊断实验室、医院和研究机构）具有不同的采购週期、监管要求和人员配备模式，所有这些都会影响技术在医疗保健途径中的部署和扩展方式。

对美洲、欧洲、中东和非洲以及亚太地区的基础设施、报销、人才和创新采用的区域洞察

区域动态对解剖病理学检测技术的采用、部署和运作有重大影响。在美洲，临床和研究实验室受益于强劲的资本市场和成熟的报销途径，从而促进了数位病理学平台和复杂分子检测的早期应用。随着从都市区医疗中心向区域参考检测中心的转变，医疗服务提供者通常强调与癌症治疗途径的整合，并与专业检测中心合作。

由于法律规范、报销结构和基础设施准备程度的差异，欧洲、中东和非洲的采用曲线各不相同。在欧洲部分地区，标准化的医疗保健系统和集中采购使得数位化工作流程能够广泛部署；而在其他地区，由于资金和劳动力的可用性参差不齐，需要製定更有针对性的分阶段采用策略。同时，在中东和非洲部分地区，能力建设倡议和官民合作关係关係正开始弥补分子检测和数位基础设施的差距。

在亚太地区，高患者数量、快速的基础设施投资以及本地製造能力的结合，正在加速高通量分子平台和自动化组织学解决方案的采用。国家策略优先考虑精准医疗和诊断现代化，推动了次世代定序、玻片扫描和远距病理学服务的快速整合。综上所述，这些区域模式表明，需要製定灵活的部署模式和针对特定区域的商业化方法，以满足临床需求和基础设施现状。

详细了解仪器、试剂和软体参与者的竞争策略、创新管道、合作模式和投资重点

该领域的企业行为体现了产品专业化、垂直整合和伙伴关係主导的扩张相结合。仪器製造商持续投资于自动化和互通性，设计可与影像分析软体和实验室资讯系统整合的玻片扫描器和实验室平台。试剂和抗体製造商专注于产品组合的广度和供应的稳定性，在专有配方和广泛的分销策略之间取得平衡，以降低临床实验室的单一来源风险。软体供应商透过检验的演算法、可扩展的云端架构和以用户为中心的介面来脱颖而出，这些介面支援常规诊断工作流程以及高级研究应用。

仪器製造商、试剂供应商和软体开发商之间的伙伴关係促成了捆绑解决方案，从而缩短了最终用户的引进週期并简化了检验工作。同时，一些公司正在进行有针对性的併购，以加速获取互补能力，例如生物资讯学、云端基础设施和细分检测专业知识。服务支援模式的重要性日益凸显，实验室现在期望获得全面的培训、远端故障排除和效能保证。最后，公司越来越关注监管途径和证据生成，优先进行临床验证研究和上市后检验，以确认诊断声明并支持付款方的主张。

建议实验室领导、技术开发人员和政策制定者采取以下行动，以加速临床应用、改善营运并提高供应弹性

临床实验室负责人应优先考虑分阶段的数位化应用策略，该策略从概念验证部署开始，逐步推进到在清晰的检验通讯协定下实现大规模生产。从远端二次抄表或高容量肿瘤板等目标用例入手，有助于组织展示临床效用，完善与资讯系统的集成，并在进行更广泛的部署之前建立机构信任。同时，采购团队应实施供应商多元化和资格确认框架，以减少对单一来源试剂和组件的依赖。

技术开发者必须投资于可互通的设计和开放标准，以简化与实验室资讯系统和电子健康记录的集成，并降低临床应用的门槛。监管参与和透明的绩效记录至关重要。开发者应进行严格的临床检验，并发布支持实际应用的同侪审查证据。政策制定者和支付方可以透过支援对经临床验证、能够显着提高诊断准确性和患者管理水平的数位和分子检测进行试点报销，来加速价值实现。

病理学家、组织学技术员和分子生物学家需要接受新平台的培训，同时各机构应组成跨职能团队，汇集实验室科学家、资料工程师和临床相关人员，将洞察实用化为诊疗路径。这些综合行动将增强韧性，优化资源配置，并实现永续应用。

简明的调查方法，说明多源资料收集、专家访谈、证据三角测量和分析保障措施，以确保严谨性

本研究采用混合方法，强调三角测量和透明度。透过对同行评审文献、监管指南文件、已发表的临床研究和公开文件进行二次分析，建立了背景基础。资讯来源，还进行了初步定性研究，包括对实验室主任、病理学主任、采购主管、技术开发人员和临床最终用户进行结构化访谈，以揭示营运现状、验证实践和策略重点。

分析保障措施包括将声明与监管部门的核准和已发表的临床证据进行交叉验证，以及基于场景的敏感性检查，以检查操作变量，例如周转要求和试剂交付前置作业时间。资料完整性流程包括检验访谈记录、主题编码以识别趋同见解，以及系统地记录假设和纳入标准。主要访谈涵盖不同的地理和地点概况，但区域差异可能因当地政策和报销状况而异。访谈参与者提供了知情同意，专有资讯根据保密规则处理。这些方法相结合，可实现严格、审核的综合，旨在为实际决策提供资讯。

总结综合技术进步、临床需求、监管压力和营运回应，为相关人员提供指导

总而言之，解剖病理学检测生态系统正处于一个关键的十字路口，技术能力正满足不断变化的临床期望。数位病理学、先进的免疫组织化学方法和不断扩展的分子诊断技术共同促成了更准确、更可操作的诊断，但也需要製定一个协调一致的整合、检验和人才培养策略。监管变化和商业动态进一步创造了一种环境，在这种环境中，韧性、适应性和证据生成是至关重要的竞争和营运差异化因素。

因此，相关人员应寻求切实可行的分阶段采用路径，加强与供应商的关係，并投资于可互通的系统，以减少整个诊断工作流程中的摩擦。透过将临床目标与强大的验证和数据管治实践相结合，实验室可以将技术能力与诊断品质和护理协调方面的可衡量改进联繫起来。最终，能够平衡临床严谨性、营运效率和策略伙伴关係的组织将最有能力提供永续的诊断价值，从而促进患者照护。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 推出用于远距离诊断协作的人工智慧驱动的数位病理平台
  • 开发用于全面肿瘤分析的多重免疫组织化学检测方法
  • 液态生物检体与组织病理学工作流程的整合，用于早期癌症检测
  • 监管核准批准推动精准医疗人工智慧病理学工具的商业化
  • 标准化数位幻灯片扫描通讯协定以提高机构之间的数据相容性
  • 引入云端基础的病理资讯系统以简化检测操作
  • 个人化肿瘤治疗计划中人工智慧预测生物标记的新兴趋势

第六章 2025年美国关税的累积影响

第七章：人工智慧2025的累积影响

8. 解剖病理学检测市场（依检测类型）

  • 数位病理学
    • 影像分析软体
    • 幻灯片扫描仪
  • 苏木精和伊红染色
  • 免疫组织化学
    • 单株抗体
    • 多株抗体
  • 分子病理学
    • 萤光原位杂合反应
    • 次世代定序
    • 聚合酵素链锁反应
  • 特殊染色技术
    • 过碘酸-希夫染色
    • 银色染色
    • 三色染色

9. 解剖病理学检测市场（依样本类型）

  • 细胞学样本
  • 冰冻切片
  • 组织切片检查

第 10 章解剖病理学测试市场（按应用）

  • 遗传疾病评估
    • 染色体异常
    • 单基因异常
  • 感染疾病检测
    • 细菌感染
    • 病毒感染
  • 肿瘤诊断
    • 乳癌
    • 肺癌
    • 摄护腺癌

第 11 章解剖病理学测试市场（按最终用户）

  • 诊断实验室
  • 医院
  • 研究所

第十二章解剖病理学检测市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章解剖病理学测试市场（按类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 解剖病理学检测市场（依国家）

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章 竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Laboratory Corporation of America Holdings
    • Quest Diagnostics Incorporated
    • Sonic Healthcare Limited
    • Eurofins Scientific SE
    • SYNLAB Holding GmbH
    • Unilabs AG
    • Bio-Reference Laboratories, Inc.
    • ARUP Laboratories, Inc.
    • Dr. Lal PathLabs Limited
    • Metropolis Healthcare Limited
Product Code: MRR-436901066173

The Anatomic Pathology Testing Market is projected to grow by USD 74.01 billion at a CAGR of 6.40% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 45.03 billion
Estimated Year [2025] USD 47.92 billion
Forecast Year [2032] USD 74.01 billion
CAGR (%) 6.40%

An introductory overview of anatomic pathology testing trends integrating technological innovation, clinical demand shifts, laboratory workflows, policy drivers

Anatomic pathology testing stands at the intersection of clinical necessity and rapid technological change, driving new expectations for diagnostic accuracy, turnaround time, and integration with therapeutic decision-making. Laboratories and diagnostic services now operate in an environment where molecular characterization, immunoprofiling and image-driven analytics must co-exist with traditional histology workflows to support precision medicine pathways. Consequently, stakeholders across clinical, research and commercial settings are recalibrating investments, partnerships and operational processes to meet rising clinical complexity while controlling costs and ensuring regulatory compliance.

Furthermore, shifts in healthcare delivery-from outpatient oncology programs to centralized reference labs-have altered specimen flows, testing volumes and the locus of diagnostic decision-making. As a result, laboratory leaders are evaluating digital and molecular toolsets not only for their diagnostic value but for their ability to integrate into electronic health records, laboratory information systems and multidisciplinary care teams. In light of these dynamics, the executive synthesis that follows highlights the major drivers reshaping practice, the structural challenges that require strategic response, and the practical considerations that decision-makers should weigh when prioritizing investments in people, technology and partnerships.

A detailed examination of transformative technological, clinical and regulatory shifts reshaping diagnostic pathways, data architecture and laboratory workforce

The landscape of anatomic pathology testing is undergoing several transformative shifts that are changing how diagnoses are made, how laboratories organize work, and how data flows between stakeholders. Digital pathology adoption has progressed from pilot installations to production deployments in many institutions, enabling whole slide imaging, remote review and the application of algorithmic image analysis. At the same time, the diffusion of artificial intelligence and machine learning into routine workflows has introduced new considerations around validation, clinical integration and regulatory clearance of diagnostic algorithms.

Concurrently, molecular pathology techniques such as next-generation sequencing, fluorescence in situ hybridization and targeted PCR are redefining diagnostic categories and therapeutic stratification. This molecular expansion necessitates increased collaboration between histopathology and molecular laboratories, and it elevates demands on bioinformatics, data storage and cross-discipline training. Regulatory attention and reimbursement frameworks are also evolving; as a result, laboratories must navigate changing validation expectations and value demonstration requirements. Lastly, workforce pressures, supply chain volatility and increasing demand for faster turnaround times are prompting laboratories to seek automation, streamlined workflows and strategic vendor partnerships to sustain quality and throughput. Taken together, these shifts are reshaping priorities across procurement, talent development and clinical service design.

A focused analysis of how United States tariff changes in 2025 are altering supply chains, procurement tactics, reagent sourcing and cross-border lab operations

United States tariff policy developments in 2025 have produced a complex set of operational and strategic effects for laboratories, manufacturers and distributors involved in anatomic pathology testing. In the short term, tariff-induced increases on imported instruments, reagents and consumables have compelled procurement teams to reassess sourcing strategies, increase inventory buffers for critical reagents and accelerate supplier qualification processes to reduce exposure to supply disruption. Consequently, procurement cycles now often include contingency clauses, alternative supplier lists and accelerated validation pathways to ensure continuity of clinical services.

Over the medium term, these trade measures have highlighted the economic and logistical value of supplier diversification and regionalized sourcing. Some clinical laboratories and manufacturing partners have pursued nearer-shore manufacturing partnerships, contract manufacturing expansions and localized warehousing to mitigate freight volatility and duty risk. At the same time, manufacturers are revisiting product design and bill-of-materials sourcing to reduce exposure to tariffed components, while service organizations are re-evaluating maintenance and spare parts strategies. Regulatory and contractual implications also surface when suppliers change sourcing origins; therefore, institutions must ensure that any substituted components meet the original performance and regulatory benchmarks.

Moreover, tariff-driven cost pressures can accelerate conversations around automation and assay consolidation that reduce per-test dependency on imported consumables. To manage these pressures, stakeholders increasingly emphasize scenario planning, multi-year supplier agreements with hedging provisions, and collaborative forecasting with supply partners. In sum, tariff dynamics in 2025 are prompting a strategic reorientation toward supply resilience, procurement agility and stronger industry-lab collaboration to safeguard diagnostic continuity.

Segmentation-focused insights across test types, sample categories, applications and end users revealing adoption dynamics, technology linkages and priorities

Analysis by test type reveals that laboratories are balancing legacy histology techniques with emergent digital and molecular modalities to create hybrid diagnostic workflows. Digital Pathology attracts investment in both image analysis software and slide scanners to enable remote review and advanced morphometric analysis, while Hematoxylin and Eosin staining remains the foundational tissue assessment method. Immunohistochemistry continues to expand its role for diagnostic and predictive testing, with laboratories weighing monoclonal versus polyclonal antibody strategies according to assay specificity and supply reliability. Molecular Pathology has become a core complement to histology; diagnostic portfolios blend fluorescence in situ hybridization, next-generation sequencing and polymerase chain reaction approaches to capture genomic alterations and actionable biomarkers. Special Staining techniques such as periodic acid-Schiff stain, silver stain and trichrome stain retain importance for niche diagnostic contexts and for distinguishing disease morphologies.

When sample type is considered, distinctions among cytology samples, frozen sections and tissue biopsy specimens drive differences in pre-analytic handling, turnaround expectations and instrumentation needs. These sample-specific demands in turn shape the workflows and validation strategies laboratories adopt. In terms of application, testing programs align with genetic disorder evaluation, infectious disease detection and oncology diagnostics. Genetic assessments further bifurcate into chromosomal versus single-gene disorder workflows, infectious disease testing delineates bacterial from viral pathogen detection strategies, and oncology protocols increasingly prioritize tumor-specific panels such as those used in breast, lung and prostate cancer contexts. Finally, end users including diagnostic laboratories, hospitals and research institutes have distinct procurement cycles, regulatory requirements and staffing models, all of which influence how technologies are deployed and scaled across care pathways.

Regional insight into infrastructure, reimbursement, talent and innovation adoption distinguishing the Americas, Europe, Middle East & Africa and Asia-Pacific

Regional dynamics exert a strong influence on the adoption, deployment and operationalization of anatomic pathology testing technologies. In the Americas, clinical and research laboratories benefit from robust capital markets and established reimbursement pathways, which facilitate early adoption of digital pathology platforms and complex molecular assays. Transitioning from urban medical centers to regional reference laboratories, providers often emphasize integration with oncology care pathways and partnerships with specialty testing centers.

In Europe, Middle East & Africa, heterogeneity in regulatory frameworks, reimbursement structures and infrastructure readiness leads to differentiated adoption curves. In parts of Europe, standardized healthcare systems and centralized procurement can support broad rollouts of validated digital workflows, whereas in other regions, variable funding and workforce availability necessitate more focused, incremental implementation strategies. Meanwhile, capacity-building initiatives and public-private partnerships in certain Middle East and African locales are beginning to address gaps in molecular testing and digital infrastructure.

Across Asia-Pacific, a combination of large patient volumes, rapid infrastructure investment and local manufacturing capabilities is accelerating uptake of both high-throughput molecular platforms and automated histology solutions. National strategies that prioritize precision medicine and diagnostic modernization are enabling faster integration of next-generation sequencing, slide scanning and telepathology services. Taken together, these regional patterns underline the need for adaptable deployment models and region-specific commercialization approaches to meet clinical demand and infrastructure realities.

An in-depth view of competitive strategies, innovation pipelines, partnership models and investment priorities among instrumentation, reagent and software players

Company behavior in this sector reflects a mix of product specialization, vertical integration and partnership-driven expansion. Instrumentation manufacturers continue to invest in automation and interoperability, designing slide scanners and laboratory platforms that integrate with image analysis software and laboratory information systems. Reagent and antibody suppliers focus on portfolio breadth and supply stability, balancing proprietary formulations with wider distribution strategies to reduce single-source risk for clinical laboratories. Software vendors are differentiating through validated algorithms, scalable cloud architectures and user-centered interfaces that support routine diagnostic workflows as well as advanced research applications.

Strategic collaboration remains a hallmark of competitive positioning: partnerships among instrument makers, reagent suppliers and software developers enable bundled solutions that shorten adoption cycles and simplify validation efforts for end users. Concurrently, some organizations pursue targeted mergers and acquisitions to accelerate access to complementary capabilities such as bioinformatics, cloud infrastructure or niche assay expertise. Service and support models have grown in importance as laboratories expect robust training, remote troubleshooting and performance guarantees. Finally, firms are increasingly attentive to regulatory pathways and evidence generation, prioritizing clinical validation studies and post-market surveillance to substantiate diagnostic claims and to support payer discussions.

Actionable recommendations for laboratory leaders, technology developers and policymakers to speed clinical adoption, improve operations and boost supply resilience

Laboratory leaders should prioritize a phased digital adoption strategy that begins with proof-of-concept deployments and progresses to scaled production under clear validation protocols. By starting with targeted use cases-such as remote secondary reads or high-volume tumor boards-organizations can demonstrate clinical utility, refine integration with information systems and build institutional confidence before committing to broader rollouts. In parallel, procurement teams should implement supplier diversification and qualification frameworks that reduce reliance on single-source reagents and parts; this will preserve operational continuity in the face of geopolitical or tariff-driven disruption.

Technology developers must invest in interoperable designs and open standards to ease integration with laboratory information systems and electronic health records, thereby lowering the barrier to clinical adoption. Regulatory engagement and transparent performance documentation are essential; developers should pursue rigorous clinical validation and publish peer-reviewed evidence that supports real-world use. Policy makers and payers can accelerate value realization by supporting pilot reimbursement schemes for clinically validated digital and molecular assays that demonstrably improve diagnostic accuracy or patient management.

Finally, workforce planning should combine targeted upskilling with role redesign: pathologists, histotechnologists and molecular specialists require training on new platforms, while organizations should create cross-functional teams that align laboratory scientists, data engineers and clinical stakeholders to operationalize insights into care pathways. These integrated actions will strengthen resilience, optimize resource allocation and enable sustainable adoption.

A concise methodology describing multi-source data collection, expert interviews, evidence triangulation and analytical safeguards applied to ensure rigor

This research applies a mixed-methods approach that emphasizes triangulation and transparency. Secondary analysis of peer-reviewed literature, regulatory guidance documents, published clinical studies and public filings established the contextual foundation. These sources were then augmented by primary qualitative research, including structured interviews with laboratory directors, heads of pathology, procurement executives, technology developers and clinical end users to surface operational realities, validation practices and strategic priorities.

Analytical safeguards included cross-validation of claims against regulatory approvals and published clinical evidence, as well as scenario-based sensitivity checks for operational variables such as turnaround requirements and reagent lead times. Data integrity processes encompassed interview transcription verification, thematic coding to identify convergent insights, and methodical documentation of assumptions and inclusion criteria. Limitations are acknowledged: while primary interviews spanned diverse geographies and institutional profiles, some regional nuance may vary by local policy and reimbursement contexts. Ethical considerations guided the work throughout; interview participants provided informed consent and proprietary information was handled under confidentiality protocols. Together, these methods support a rigorous and auditable synthesis intended to inform practical decision-making.

A concluding synthesis linking technological advances, clinical imperatives, regulatory pressures and operational responses to provide guidance for stakeholders

In conclusion, the anatomic pathology testing ecosystem is at a pivotal juncture where technological capability meets evolving clinical expectations. Digital pathology, advanced immunohistochemistry approaches and expanding molecular diagnostics collectively enable more precise, actionable diagnoses, but they also demand cohesive strategies for integration, validation and workforce development. Regulatory shifts and trade dynamics further contribute to an environment where resilience, adaptability and evidence generation are decisive competitive and operational differentiators.

Therefore, stakeholders should pursue pragmatic, staged adoption pathways, strengthen supplier relationships and invest in interoperable systems that reduce friction across diagnostic workflows. By aligning clinical objectives with robust validation and data governance practices, laboratories can translate technological potential into measurable improvements in diagnostic quality and care coordination. Ultimately, the organizations that balance clinical rigor, operational efficiency and strategic partnerships will be best positioned to deliver sustainable diagnostic value in service of patient care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Adoption of AI-driven digital pathology platforms for remote diagnostic collaboration
  • 5.2. Development of multiplex immunohistochemistry assays for comprehensive tumor profiling
  • 5.3. Emergence of liquid biopsy integration with histopathology workflows for early cancer detection
  • 5.4. Regulatory approvals driving the commercialization of AI pathology tools for precision medicine
  • 5.5. Standardization of digital slide scanning protocols to improve cross-institutional data compatibility
  • 5.6. Implementation of cloud-based pathology information systems to streamline lab operations
  • 5.7. Emerging trend of AI-enabled predictive biomarkers for personalized oncology treatment planning

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Anatomic Pathology Testing Market, by Test Type

  • 8.1. Digital Pathology
    • 8.1.1. Image Analysis Software
    • 8.1.2. Slide Scanners
  • 8.2. Hematoxylin And Eosin Staining
  • 8.3. Immunohistochemistry
    • 8.3.1. Monoclonal Antibody
    • 8.3.2. Polyclonal Antibody
  • 8.4. Molecular Pathology
    • 8.4.1. Fluorescence In Situ Hybridization
    • 8.4.2. Next Generation Sequencing
    • 8.4.3. Polymerase Chain Reaction
  • 8.5. Special Staining
    • 8.5.1. Periodic Acid-Schiff Stain
    • 8.5.2. Silver Stain
    • 8.5.3. Trichrome Stain

9. Anatomic Pathology Testing Market, by Sample Type

  • 9.1. Cytology Samples
  • 9.2. Frozen Sections
  • 9.3. Tissue Biopsy

10. Anatomic Pathology Testing Market, by Application

  • 10.1. Genetic Disorders
    • 10.1.1. Chromosomal Disorders
    • 10.1.2. Single Gene Disorders
  • 10.2. Infectious Diseases
    • 10.2.1. Bacterial Infections
    • 10.2.2. Viral Infections
  • 10.3. Oncology
    • 10.3.1. Breast Cancer
    • 10.3.2. Lung Cancer
    • 10.3.3. Prostate Cancer

11. Anatomic Pathology Testing Market, by End User

  • 11.1. Diagnostic Laboratories
  • 11.2. Hospitals
  • 11.3. Research Institutes

12. Anatomic Pathology Testing Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Anatomic Pathology Testing Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Anatomic Pathology Testing Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Laboratory Corporation of America Holdings
    • 15.3.2. Quest Diagnostics Incorporated
    • 15.3.3. Sonic Healthcare Limited
    • 15.3.4. Eurofins Scientific SE
    • 15.3.5. SYNLAB Holding GmbH
    • 15.3.6. Unilabs AG
    • 15.3.7. Bio-Reference Laboratories, Inc.
    • 15.3.8. ARUP Laboratories, Inc.
    • 15.3.9. Dr. Lal PathLabs Limited
    • 15.3.10. Metropolis Healthcare Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. ANATOMIC PATHOLOGY TESTING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. ANATOMIC PATHOLOGY TESTING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ANATOMIC PATHOLOGY TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIGITAL PATHOLOGY, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIGITAL PATHOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIGITAL PATHOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIGITAL PATHOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIGITAL PATHOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIGITAL PATHOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIGITAL PATHOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMAGE ANALYSIS SOFTWARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMAGE ANALYSIS SOFTWARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMAGE ANALYSIS SOFTWARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMAGE ANALYSIS SOFTWARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMAGE ANALYSIS SOFTWARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMAGE ANALYSIS SOFTWARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SLIDE SCANNERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SLIDE SCANNERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SLIDE SCANNERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SLIDE SCANNERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SLIDE SCANNERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SLIDE SCANNERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY HEMATOXYLIN AND EOSIN STAINING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY HEMATOXYLIN AND EOSIN STAINING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY HEMATOXYLIN AND EOSIN STAINING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY HEMATOXYLIN AND EOSIN STAINING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY HEMATOXYLIN AND EOSIN STAINING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY HEMATOXYLIN AND EOSIN STAINING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MONOCLONAL ANTIBODY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MONOCLONAL ANTIBODY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MONOCLONAL ANTIBODY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MONOCLONAL ANTIBODY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MONOCLONAL ANTIBODY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MONOCLONAL ANTIBODY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY POLYCLONAL ANTIBODY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY POLYCLONAL ANTIBODY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY POLYCLONAL ANTIBODY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY POLYCLONAL ANTIBODY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY POLYCLONAL ANTIBODY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY POLYCLONAL ANTIBODY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MOLECULAR PATHOLOGY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MOLECULAR PATHOLOGY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MOLECULAR PATHOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MOLECULAR PATHOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MOLECULAR PATHOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MOLECULAR PATHOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MOLECULAR PATHOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MOLECULAR PATHOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SPECIAL STAINING, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SPECIAL STAINING, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SPECIAL STAINING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SPECIAL STAINING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SPECIAL STAINING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SPECIAL STAINING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SPECIAL STAINING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SPECIAL STAINING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY PERIODIC ACID-SCHIFF STAIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY PERIODIC ACID-SCHIFF STAIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY PERIODIC ACID-SCHIFF STAIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY PERIODIC ACID-SCHIFF STAIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY PERIODIC ACID-SCHIFF STAIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY PERIODIC ACID-SCHIFF STAIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SILVER STAIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SILVER STAIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SILVER STAIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SILVER STAIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SILVER STAIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SILVER STAIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TRICHROME STAIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TRICHROME STAIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TRICHROME STAIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TRICHROME STAIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TRICHROME STAIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TRICHROME STAIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY CYTOLOGY SAMPLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY CYTOLOGY SAMPLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY CYTOLOGY SAMPLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY CYTOLOGY SAMPLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY CYTOLOGY SAMPLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY CYTOLOGY SAMPLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY FROZEN SECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY FROZEN SECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY FROZEN SECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY FROZEN SECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY FROZEN SECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY FROZEN SECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TISSUE BIOPSY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TISSUE BIOPSY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TISSUE BIOPSY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TISSUE BIOPSY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TISSUE BIOPSY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TISSUE BIOPSY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY GENETIC DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY GENETIC DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY GENETIC DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY GENETIC DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY GENETIC DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY GENETIC DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY CHROMOSOMAL DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY CHROMOSOMAL DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY CHROMOSOMAL DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY CHROMOSOMAL DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY CHROMOSOMAL DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY CHROMOSOMAL DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SINGLE GENE DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SINGLE GENE DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SINGLE GENE DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SINGLE GENE DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SINGLE GENE DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SINGLE GENE DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY BACTERIAL INFECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY BACTERIAL INFECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY BACTERIAL INFECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY BACTERIAL INFECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY VIRAL INFECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY VIRAL INFECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY VIRAL INFECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY VIRAL INFECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY BREAST CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY BREAST CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY LUNG CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY LUNG CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. AMERICAS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 216. AMERICAS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 217. AMERICAS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 218. AMERICAS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 219. AMERICAS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2024 (USD MILLION)
  • TABLE 220. AMERICAS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIGITAL PATHOLOGY, 2025-2032 (USD MILLION)
  • TABLE 221. AMERICAS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2024 (USD MILLION)
  • TABLE 222. AMERICAS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2025-2032 (USD MILLION)
  • TABLE 223. AMERICAS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MOLECULAR PATHOLOGY, 2018-2024 (USD MILLION)
  • TABLE 224. AMERICAS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MOLECULAR PATHOLOGY, 2025-2032 (USD MILLION)
  • TABLE 225. AMERICAS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SPECIAL STAINING, 2018-2024 (USD MILLION)
  • TABLE 226. AMERICAS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SPECIAL STAINING, 2025-2032 (USD MILLION)
  • TABLE 227. AMERICAS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 228. AMERICAS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 229. AMERICAS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 230. AMERICAS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 231. AMERICAS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY GENETIC DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 232. AMERICAS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY GENETIC DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 233. AMERICAS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 234. AMERICAS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 235. AMERICAS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 236. AMERICAS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 237. AMERICAS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 238. AMERICAS ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 239. NORTH AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. NORTH AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. NORTH AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 242. NORTH AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2024 (USD MILLION)
  • TABLE 244. NORTH AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIGITAL PATHOLOGY, 2025-2032 (USD MILLION)
  • TABLE 245. NORTH AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2024 (USD MILLION)
  • TABLE 246. NORTH AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2025-2032 (USD MILLION)
  • TABLE 247. NORTH AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MOLECULAR PATHOLOGY, 2018-2024 (USD MILLION)
  • TABLE 248. NORTH AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MOLECULAR PATHOLOGY, 2025-2032 (USD MILLION)
  • TABLE 249. NORTH AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SPECIAL STAINING, 2018-2024 (USD MILLION)
  • TABLE 250. NORTH AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SPECIAL STAINING, 2025-2032 (USD MILLION)
  • TABLE 251. NORTH AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 252. NORTH AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 253. NORTH AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 254. NORTH AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 255. NORTH AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY GENETIC DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 256. NORTH AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY GENETIC DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 257. NORTH AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 258. NORTH AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 259. NORTH AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 260. NORTH AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 261. NORTH AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 262. NORTH AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 263. LATIN AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. LATIN AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. LATIN AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 266. LATIN AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 267. LATIN AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2024 (USD MILLION)
  • TABLE 268. LATIN AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIGITAL PATHOLOGY, 2025-2032 (USD MILLION)
  • TABLE 269. LATIN AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2024 (USD MILLION)
  • TABLE 270. LATIN AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2025-2032 (USD MILLION)
  • TABLE 271. LATIN AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MOLECULAR PATHOLOGY, 2018-2024 (USD MILLION)
  • TABLE 272. LATIN AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY MOLECULAR PATHOLOGY, 2025-2032 (USD MILLION)
  • TABLE 273. LATIN AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SPECIAL STAINING, 2018-2024 (USD MILLION)
  • TABLE 274. LATIN AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SPECIAL STAINING, 2025-2032 (USD MILLION)
  • TABLE 275. LATIN AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 276. LATIN AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 277. LATIN AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 278. LATIN AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 279. LATIN AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY GENETIC DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 280. LATIN AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY GENETIC DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 281. LATIN AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 282. LATIN AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 283. LATIN AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 284. LATIN AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 285. LATIN AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 286. LATIN AMERICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPE, MIDDLE EAST & AFRICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPE, MIDDLE EAST & AFRICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPE, MIDDLE EAST & AFRICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPE, MIDDLE EAST & AFRICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPE, MIDDLE EAST & AFRICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIGITAL PATHOLOGY, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPE, MIDDLE EAST & AFRICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY DIGITAL PATHOLOGY, 2025-2032 (USD MILLION)
  • TABLE 293. EUROPE, MIDDLE EAST & AFRICA ANATOMIC PATHOLOGY TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2024 (USD MILLION)
  • TABLE 294. EUROPE, MIDDLE EAST & AFRICA AN